Image de couverture de livre

Editorial: Advanced glycation end products ‐ a dietary culprit for IBD in the genetically susceptible?

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Fahim Ebrahimi, Anders Forss
Format:	Artículo Open Access
Publié:	Wiley 2024
Sujets:	Alimentary Pharmacology & Therapeutics
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Editorial: Getting to the Heart of the Matter in IBD—Authors' Reply
par: Ramin Ebrahimi, et autres
Publié: (2025)

The contribution of dietary advanced glycation end‐products and genetic risk in the development of inflammatory bowel disease: a prospective cohort study
par: Fangyuan Jiang, et autres
Publié: (2024)

Editorial: Time to address quality of life in our IBD treatment—IBD nurse intervention as a key part of multimodal IBD management
par: Jakob B. Seidelin
Publié: (2024)

Editorial: Getting to the Heart of the Matter in IBD
par: Ashwin N. Ananthakrishnan
Publié: (2025)

Letter: Geographic Transportability of Shingles Risk With Advanced IBD Therapies
par: Guofu Mao, et autres
Publié: (2026)

Editorial: Targeting Urgency in IBD —A Historical Divide
par: Daniele Noviello, et autres
Publié: (2025)

Editorial: Inflammation and Not Glucocorticoid Therapy is the Key Driver of Fracture Risk in IBD
par: Darcy Quinn Holt, et autres
Publié: (2024)

Editorial: Updated COVID‐19 Boosters—Tailoring Protection for Patients With IBD
par: James L. Alexander, et autres
Publié: (2024)

Editorial: Targeting Urgency in IBD —A Historical Divide. Authors' Reply
par: Parul Tandon, et autres
Publié: (2025)

Editorial: Shingles Risk in IBD —More Evidence to Support Routine Preventive Vaccination?
par: Keith Bodger
Publié: (2025)

Editorial: Toward Safer Pain Management in IBD—Lessons From Prescription Patterns
par: Shabari Shenoy, et autres
Publié: (2025)

Editorial: Disentangling Early‐Life Antibiotics and Infections as Risk Factors for the Development of Childhood IBD
par: Katherine L. Stone, et autres
Publié: (2024)

Editorial: Toward Safer Pain Management in IBD—Lessons From Prescription Patterns. Authors' Reply
par: Samantha Baillie, et autres
Publié: (2025)

Impact of inflammatory bowel disease on the risk of acute coronary syndrome: A Swedish Nationwide Cohort Study
par: Carl Eriksson, et autres
Publié: (2024)

Editorial: Redefining Safety in Post‐Liver Transplant IBD —Why Therapeutic Effectiveness Is the Ultimate Shield. Authors' Reply
par: Simone Chin, et autres
Publié: (2025)

Letter: Addressing opioid exposure and associated harms in patients with IBD
par: Christian P. Selinger, et autres
Publié: (2024)

Letter: The Hidden Truth of IBD Risk—From Antibiotics to Environmental Factors
par: Xueneng Yang, et autres
Publié: (2025)

Review Article: Green Management of IBD—New Paradigms for an Eco‐Friendly Approach
par: Giovanni Cammarota, et autres
Publié: (2024)

Faecal biomarkers for diagnosis and prediction of disease course in treatment‐naïve patients with IBD
par: Maria Ling Lundström, et autres
Publié: (2024)

Treatment‐Free Outcomes Following Surgery for IBD : A Nationwide Cohort Study
par: Adam S. Faye, et autres
Publié: (2025)

Letter: Diet to Modify Risk of IBD—More Plants and Less Processed Food?
par: Alice S. Day, et autres
Publié: (2025)

Editorial: Can dietary gluten restriction improve hepatic steatosis?
par: Hariklia Kranidioti, et autres
Publié: (2024)

Letter: Differences in Disease Characteristics and Treatment Exposures Between Paediatric and Adult‐Onset IBD
par: Xinli Chen, et autres
Publié: (2024)

The Effectiveness of Medical Therapies for Joint, Skin and Eye Extraintestinal Manifestations in IBD—An Umbrella Review
par: Olga M. Nardone, et autres
Publié: (2025)

Review Article: TL1A Inhibitors in IBD ‐ Mechanistic Rationale and Clinical Evidence
par: Manjeet Kumar Goyal, et autres
Publié: (2026)

Editorial: PSC as an Independent Risk Factor for CRC Without IBD : Can Observed Epidemiological Trends Help Uncover Biological Mechanisms and Guide Surveillance Strategies?
par: Natassia Tan, et autres
Publié: (2025)

Letter: Unlocking the Full Potential of Dietary Therapy in IBD —The Case for Universal Eating Disorder Screening
par: Luisa Bertin, et autres
Publié: (2026)

Letter: Are Antispasmodics Truly Ineffective in IBD? Considerations on Nuanced Interpretation and Stratified Analysis. Authors' Reply
par: Chachrit Khunsriraksakul, et autres
Publié: (2025)

Letter: Intestinal permeability accounting for ongoing gastrointestinal symptoms following endoscopic remission in IBD—Authors' reply
par: Arta Aliu, et autres
Publié: (2024)

Letter: Double‐Dose Hepatitis B Vaccination in IBD —A Step Forward in Protecting Immunosuppressed Patients
par: Luisa Bertin, et autres
Publié: (2026)

Review article: Evidence‐based dietary management of inflammatory bowel disease
par: Peter R. Gibson, et autres
Publié: (2024)

Editorial: The microbiome and gastric mucosal protection in aspirin users—Authors' reply
par: Nina Løn, et autres
Publié: (2024)

Letter: Effect of dietary additives on intestinal barrier and acute stress in healthy adults
par: Liqi Li
Publié: (2024)

Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis‐associated inflammatory bowel disease (PSC‐IBD): A matched analysis from the Paediatric PSC Consortium
par: Amanda Ricciuto, et autres
Publié: (2024)

Editorial: Obesity and Outcomes on Advanced Therapy in Ulcerative Colitis—The Fat of the Matter
par: Anish J. Kuriakose Kuzhiyanjal, et autres
Publié: (2025)

Editorial: Advancing HCC Surveillance in Hepatitis B With Biomarker‐Based Strategy
par: Yu Jun Wong
Publié: (2025)

Letter: Diet‐microbiome interactions in inflammatory bowel disease—Navigating towards individualised dietary strategies
par: Iris Barth, et autres
Publié: (2024)

Editorial: Dual Advanced Therapy in Refractory Ulcerative Colitis—Hope Beyond Monotherapy
par: Ahmed B. Bayoumy, et autres
Publié: (2025)

Editorial: Does Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ) With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease?
par: C. C. Mark Cheah, et autres
Publié: (2025)

Editorial: Advancing HCC Surveillance in Hepatitis B With Biomarker‐Based Strategy—Authors' Reply
par: Tanat Saeoui, et autres
Publié: (2025)